These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 34542301)
21. Characteristics and risk factors of mortality in patients with systemic sclerosis-associated interstitial lung disease. Jang HJ; Woo A; Kim SY; Yong SH; Park Y; Chung K; Lee SH; Leem AY; Lee SH; Kim EY; Jung JY; Kang YA; Kim YS; Park MS Ann Med; 2023 Dec; 55(1):663-671. PubMed ID: 37074318 [TBL] [Abstract][Full Text] [Related]
22. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis. Ueda T; Sakagami T; Kikuchi T; Takada T Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675 [TBL] [Abstract][Full Text] [Related]
23. Interstitial lung disease in systemic sclerosis: current and future treatment. Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071 [TBL] [Abstract][Full Text] [Related]
24. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis. Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424 [TBL] [Abstract][Full Text] [Related]
25. Correlation between Interstitial Lung Disease Morphology Scores Based on High-resolution Computed Tomography Chest and Skin Fibrosis Degree Based on Modified Rodnan's Skin Score on Systemic Sclerosis. Hikmat IH; Ramdhini SS; Soekersi H; Dewi S Acta Med Indones; 2021 Jul; 53(3):254-260. PubMed ID: 34611063 [TBL] [Abstract][Full Text] [Related]
26. Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study. Hamberg V; Sohrabian A; Volkmann ER; Wildt M; Löfdahl A; Wuttge DM; Hesselstrand R; Dellgren G; Westergren-Thorsson G; Rönnelid J; Andréasson K Arthritis Res Ther; 2023 Sep; 25(1):162. PubMed ID: 37667402 [TBL] [Abstract][Full Text] [Related]
27. Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease. Junfei Z; Meihua G; Shuai Z; Xiangting L; Zhidan L; Tianming C; Yajing L; Chu T; Lipu S Clin Rheumatol; 2023 Oct; 42(10):2823-2832. PubMed ID: 37335409 [TBL] [Abstract][Full Text] [Related]
28. Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis. Khanna SA; Nance JW; Suliman SA Curr Rheumatol Rep; 2022 May; 24(5):166-173. PubMed ID: 35499699 [TBL] [Abstract][Full Text] [Related]
29. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database. Funatogawa T; Narita Y; Tamura A; Mii K; Sugitani Y; Uchida T Mod Rheumatol; 2022 Jul; 32(4):755-760. PubMed ID: 34850080 [TBL] [Abstract][Full Text] [Related]
30. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326 [TBL] [Abstract][Full Text] [Related]
31. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Distler O; Assassi S; Cottin V; Cutolo M; Danoff SK; Denton CP; Distler JHW; Hoffmann-Vold AM; Johnson SR; Müller Ladner U; Smith V; Volkmann ER; Maher TM Eur Respir J; 2020 May; 55(5):. PubMed ID: 32079645 [TBL] [Abstract][Full Text] [Related]